Conversion to belatacept after lung transplantation: Report of 10 cases.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
09
2022
accepted:
24
01
2023
entrez:
15
3
2023
pubmed:
16
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
Calcineurin inhibitors (CNIs) remain the cornerstone of maintenance immunosuppression (IS) after lung transplantation (LTx), although CNI-related life-threatening toxic effects may occur. Belatacept, a novel immunosuppressant that blocks a T-cell co-stimulation pathway, is a non-nephrotoxic drug indicated as an alternative to CNIs in kidney Tx. In LTx, there are only a few reports of belatacept conversion as a CNI-free or CNI-sparing IS treatment. We reviewed a series of 10 LTx recipients with conversion to a CNI-free belatacept IS regimen within the first year post-LTx (n = 7) or a belatacept/low-dose CNI combination after the first year (n = 3). Use of belatacept was triggered by severe renal failure in 9 patients and under-IS with previous other IS-related toxicities in 1 patient. Mean estimated glomerular filtration rate after starting belatacept significantly improved at 6 months after initiation and at the last-follow-up (p = 0.006, and p = 0.002 respectively). The incidence of recurrent and/or severe acute cellular rejection (ACR) episodes was high in patients with CNI-free belatacept-based IS (n = 4/7). Chronic graft allograft dysfunction developed in 2 of 9 recipients under belatacept IS. Belatacept was stopped in 6 patients because of recurrent/severe ACR (n = 3), recurrent opportunistic infections (n = 1), center modified policy (n = 1), or other cause (n = 1). Early conversion to CNI-free belatacept-based IS improved renal function in this series but was counterbalanced by a high incidence of recurrent ACR, including life-threatening episodes. Other studies are needed to better determine the indications for its use after LTx, possibly with lower immunological risk IS regimens, such as CNI-sparing belatacept.
Sections du résumé
BACKGROUND
Calcineurin inhibitors (CNIs) remain the cornerstone of maintenance immunosuppression (IS) after lung transplantation (LTx), although CNI-related life-threatening toxic effects may occur. Belatacept, a novel immunosuppressant that blocks a T-cell co-stimulation pathway, is a non-nephrotoxic drug indicated as an alternative to CNIs in kidney Tx. In LTx, there are only a few reports of belatacept conversion as a CNI-free or CNI-sparing IS treatment.
METHODS
We reviewed a series of 10 LTx recipients with conversion to a CNI-free belatacept IS regimen within the first year post-LTx (n = 7) or a belatacept/low-dose CNI combination after the first year (n = 3).
RESULTS
Use of belatacept was triggered by severe renal failure in 9 patients and under-IS with previous other IS-related toxicities in 1 patient. Mean estimated glomerular filtration rate after starting belatacept significantly improved at 6 months after initiation and at the last-follow-up (p = 0.006, and p = 0.002 respectively). The incidence of recurrent and/or severe acute cellular rejection (ACR) episodes was high in patients with CNI-free belatacept-based IS (n = 4/7). Chronic graft allograft dysfunction developed in 2 of 9 recipients under belatacept IS. Belatacept was stopped in 6 patients because of recurrent/severe ACR (n = 3), recurrent opportunistic infections (n = 1), center modified policy (n = 1), or other cause (n = 1).
CONCLUSION
Early conversion to CNI-free belatacept-based IS improved renal function in this series but was counterbalanced by a high incidence of recurrent ACR, including life-threatening episodes. Other studies are needed to better determine the indications for its use after LTx, possibly with lower immunological risk IS regimens, such as CNI-sparing belatacept.
Identifiants
pubmed: 36920935
doi: 10.1371/journal.pone.0281492
pii: PONE-D-22-26417
pmc: PMC10016650
doi:
Substances chimiques
Abatacept
7D0YB67S97
Calcineurin Inhibitors
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0281492Informations de copyright
Copyright: © 2023 Brugière et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Arch Bronconeumol. 2008 Jul;44(7):353-9
pubmed: 18727887
J Heart Lung Transplant. 2007 Dec;26(12):1229-42
pubmed: 18096473
Am J Transplant. 2017 Nov;17(11):2922-2936
pubmed: 28544101
Transplantation. 2018 Jun;102(6):e255-e256
pubmed: 29509571
Transplant Proc. 2016 Jan-Feb;48(1):275-8
pubmed: 26915884
J Heart Lung Transplant. 2015 May;34(5):625-30
pubmed: 25577564
Am J Transplant. 2020 Feb;20(2):553-563
pubmed: 31452337
Am J Transplant. 2012 Jan;12(1):210-7
pubmed: 21992533
Transplant Proc. 2022 Jan-Feb;54(1):165-168
pubmed: 34756649
Transplantation. 2018 Sep;102(9):1440-1452
pubmed: 29787522
Am J Transplant. 2022 Jul;22(7):1884-1892
pubmed: 35286760
Clin J Am Soc Nephrol. 2013 Jan;8(1):19-25
pubmed: 23037982
Neurocrit Care. 2018 Feb;28(1):4-11
pubmed: 28251577
PLoS One. 2020 Oct 15;15(10):e0240335
pubmed: 33057374
J Am Soc Nephrol. 2007 Dec;18(12):3031-41
pubmed: 18039925
Eur Respir J. 2014 Dec;44(6):1479-503
pubmed: 25359357
Am J Transplant. 2005 Jun;5(6):1469-76
pubmed: 15888056
Am J Transplant. 2017 Sep;17(9):2350-2362
pubmed: 28502091
Transpl Infect Dis. 2017 Aug;19(4):
pubmed: 28401625
Transplantation. 2013 Mar 15;95(5):761-5
pubmed: 23296148
Transplantation. 2018 Sep;102(9):1545-1552
pubmed: 29570163
N Engl J Med. 2016 Jan 28;374(4):333-43
pubmed: 26816011
Transplantation. 2018 Jan;102(1):171-177
pubmed: 28691954
Am J Transplant. 2010 Mar;10(3):535-46
pubmed: 20415897
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Am J Transplant. 2017 Sep;17(9):2235-2237
pubmed: 28613437
Am J Transplant. 2020 Apr;20(4):1039-1055
pubmed: 31680394
Am J Transplant. 2017 Sep;17(9):2285-2299
pubmed: 28502128
J Investig Med High Impact Case Rep. 2014 Sep 22;2(3):2324709614546866
pubmed: 26425619
Am J Transplant. 2015 Oct;15(10):2726-31
pubmed: 25988397
Transpl Int. 2016 Apr;29(4):453-63
pubmed: 26678245